首页 > 最新文献

Expert Review of Gastroenterology & Hepatology最新文献

英文 中文
Diagnosis and management of pancreatic insufficiency in patients with gastrectomy due to cancer or gastric ulcers: a virtual roundtable expert discussion. 癌症或胃溃疡导致胃切除术患者胰腺功能不全的诊断和管理:虚拟圆桌专家讨论。
IF 3.9 3区 医学 Q2 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2023-12-01 Epub Date: 2024-01-17 DOI: 10.1080/17474124.2023.2296762
Daniel Croagh, Christoph W Michalski, Mark I van Berge Henegouwen, Sergio Alfieri

Introduction: Pancreatic exocrine insufficiency (PEI) is common after gastric resection for cancer or ulcers but is under-recognized and undertreated. Although pancreatic enzyme replacement therapy (PERT) is the mainstay of PEI management, robust evidence supporting its use after gastric surgery is limited.

Areas covered: In the absence of guideline recommendations specific for patients with pancreatic insufficiency after gastrectomy, a panel of experts from different geographical regions convened in a virtual meeting to discuss their approach to patient management.

Expert opinion: Pancreatic insufficiency after gastrointestinal surgery is not a simple post-surgical complication as several factors contribute to its development. Although the pancreas is unimpaired after gastrectomy, it cannot function normally in the altered environment. Pancreatic insufficiency can be challenging to diagnose in gastrectomy patients due to nonspecific symptoms and the absence of a simple diagnostic test. Fecal elastase appears to be the default test, although it is not sufficiently sensitive nor reliable for diagnosing or monitoring PEI. Patients with maldigestion symptoms after gastrectomy are treated pragmatically: those with clinical suspicion of pancreatic insufficiency receive a trial of PERT and are monitored for symptom improvement. There is a clear need for high-quality evidence from clinical trials to guide the management of this patient population.

简介:胰腺外分泌功能不全(PEI)是因癌症或溃疡而进行胃切除术后的常见病,但却未得到充分认识和治疗。虽然胰酶替代疗法(PERT)是治疗胰腺外分泌功能不全的主要方法,但支持胃手术后使用该疗法的有力证据却很有限:由于缺乏专门针对胃切除术后胰腺功能不全患者的指南建议,来自不同地区的专家小组召开了一次虚拟会议,讨论他们管理患者的方法:胃肠道手术后胰腺功能不全并不是一种简单的术后并发症,因为有多种因素会导致其发生。虽然胃切除术后胰腺功能未受损害,但它在改变的环境中无法正常工作。由于症状不具特异性且缺乏简单的诊断测试,胃切除术患者胰腺功能不全的诊断具有挑战性。粪便弹性蛋白酶似乎是默认的检测方法,但它在诊断或监测胰腺机能不全方面不够敏感和可靠。对胃切除术后出现消化不良症状的患者采取务实的治疗方法:临床怀疑胰腺功能不全的患者接受 PERT 试验,并监测症状改善情况。目前显然需要来自临床试验的高质量证据来指导这类患者的治疗。
{"title":"Diagnosis and management of pancreatic insufficiency in patients with gastrectomy due to cancer or gastric ulcers: a virtual roundtable expert discussion.","authors":"Daniel Croagh, Christoph W Michalski, Mark I van Berge Henegouwen, Sergio Alfieri","doi":"10.1080/17474124.2023.2296762","DOIUrl":"10.1080/17474124.2023.2296762","url":null,"abstract":"<p><strong>Introduction: </strong>Pancreatic exocrine insufficiency (PEI) is common after gastric resection for cancer or ulcers but is under-recognized and undertreated. Although pancreatic enzyme replacement therapy (PERT) is the mainstay of PEI management, robust evidence supporting its use after gastric surgery is limited.</p><p><strong>Areas covered: </strong>In the absence of guideline recommendations specific for patients with pancreatic insufficiency after gastrectomy, a panel of experts from different geographical regions convened in a virtual meeting to discuss their approach to patient management.</p><p><strong>Expert opinion: </strong>Pancreatic insufficiency after gastrointestinal surgery is not a simple post-surgical complication as several factors contribute to its development. Although the pancreas is unimpaired after gastrectomy, it cannot function normally in the altered environment. Pancreatic insufficiency can be challenging to diagnose in gastrectomy patients due to nonspecific symptoms and the absence of a simple diagnostic test. Fecal elastase appears to be the default test, although it is not sufficiently sensitive nor reliable for diagnosing or monitoring PEI. Patients with maldigestion symptoms after gastrectomy are treated pragmatically: those with clinical suspicion of pancreatic insufficiency receive a trial of PERT and are monitored for symptom improvement. There is a clear need for high-quality evidence from clinical trials to guide the management of this patient population.</p>","PeriodicalId":12257,"journal":{"name":"Expert Review of Gastroenterology & Hepatology","volume":" ","pages":"1313-1319"},"PeriodicalIF":3.9,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138802135","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Noninvasive electrical neuromodulation for gastrointestinal motility disorders. 胃肠运动障碍的无创神经电调节。
IF 3.9 3区 医学 Q2 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2023-12-01 Epub Date: 2024-01-17 DOI: 10.1080/17474124.2023.2288156
Jieyun Yin, Jiande Dz Chen

Introduction: Gastrointestinal motility disorders are highly prevalent without satisfactory treatment. noninvasive electrical neuromodulation is an emerging therapy for treating various gastrointestinal motility disorders.

Areas covered: In this review, several emerging noninvasive neuromodulation methods are introduced, including transcutaneous auricular vagal nerve stimulation, percutaneous auricular vagal nerve stimulation, transcutaneous cervical vagal nerve stimulation, transcutaneous electrical acustimulation, transabdominal interference stimulation, tibial nerve stimulation, and translumbosacral neuromodulation therapy. Their clinical applications in the most common gastrointestinal motility are discussed, including gastroesophageal reflux disease, functional dyspepsia, gastroparesis, functional constipation, irritable bowel syndrome, and fecal incontinence. PubMed database was searched from 1995 to June 2023 for relevant articles in English.

Expert opinion: Noninvasive neuromodulation is effective and safe in improving both gastrointestinal symptoms and dysmotility; it can be used when pharmacotherapy is ineffective. Future directions include refining the methodology, improving device development and understanding mechanisms of action.

胃肠运动障碍是一种非常普遍的疾病,但治疗不力。无创神经电调节是治疗各种胃肠运动障碍的一种新兴疗法。涵盖领域:本文介绍了几种新兴的无创伤神经调节方法,包括经皮耳迷走神经刺激、经皮耳迷走神经刺激、经皮颈迷走神经刺激、经皮电刺激、经腹干扰刺激、胫神经刺激和经腰骶神经调节疗法。讨论了它们在最常见的胃肠道运动中的临床应用,包括胃食管反流病、功能性消化不良、胃轻瘫、功能性便秘、肠易激综合征和大便失禁。检索PubMed数据库1995年至2023年6月的相关英文文章。专家意见:无创神经调节在改善胃肠道症状和运动障碍方面是有效和安全的;当药物治疗无效时可以使用它。未来的方向包括改进方法,改进设备开发和理解作用机制。
{"title":"Noninvasive electrical neuromodulation for gastrointestinal motility disorders.","authors":"Jieyun Yin, Jiande Dz Chen","doi":"10.1080/17474124.2023.2288156","DOIUrl":"10.1080/17474124.2023.2288156","url":null,"abstract":"<p><strong>Introduction: </strong>Gastrointestinal motility disorders are highly prevalent without satisfactory treatment. noninvasive electrical neuromodulation is an emerging therapy for treating various gastrointestinal motility disorders.</p><p><strong>Areas covered: </strong>In this review, several emerging noninvasive neuromodulation methods are introduced, including transcutaneous auricular vagal nerve stimulation, percutaneous auricular vagal nerve stimulation, transcutaneous cervical vagal nerve stimulation, transcutaneous electrical acustimulation, transabdominal interference stimulation, tibial nerve stimulation, and translumbosacral neuromodulation therapy. Their clinical applications in the most common gastrointestinal motility are discussed, including gastroesophageal reflux disease, functional dyspepsia, gastroparesis, functional constipation, irritable bowel syndrome, and fecal incontinence. PubMed database was searched from 1995 to June 2023 for relevant articles in English.</p><p><strong>Expert opinion: </strong>Noninvasive neuromodulation is effective and safe in improving both gastrointestinal symptoms and dysmotility; it can be used when pharmacotherapy is ineffective. Future directions include refining the methodology, improving device development and understanding mechanisms of action.</p>","PeriodicalId":12257,"journal":{"name":"Expert Review of Gastroenterology & Hepatology","volume":" ","pages":"1221-1232"},"PeriodicalIF":3.9,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10842705/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138451321","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
To STRIDE or not to STRIDE: a critique of "treat to target" in Crohn´s disease. STRIDE与否:对克罗恩病 "靶向治疗 "的批判。
IF 3.9 3区 医学 Q2 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2023-12-01 Epub Date: 2024-01-17 DOI: 10.1080/17474124.2023.2296564
Klaus R Herrlinger, Eduard F Stange

Introduction: The STRIDE consensus suggested to focus on mucosal healing, based on biomarkers and endoscopy, in addition to clinical endpoints as treatment target. This narrative review provides a critique of this concept in Crohn´s disease.

Areas covered: We analyze and discuss the limitations of endpoints as targets, their currently limited achievability, and the controversial evidence relating to 'treat to target.' The relevant publications in Pubmed were identified in a literature review with the key word 'Crohn´s disease.'

Expert opinion: All targets and endpoints have their limitations, and, even if reached, not all have unequivocally been shown to improve prognosis. The major deficiency of STRIDE is not only the lack of validation and agreement upon endpoints but little evidence of their achievability in a sizable proportion of patients by dose or timing adjustments or switching the medication. Above all, the concept should be based on clear evidence that patients indeed benefit from appropriate escalation of treatment and relevant controlled studies in this regard have been controversial. Until the STRIDE approach is proven to be superior to standard treatment focusing on clinical well-being, the field should remain reluctant and expect more convincing evidence before new targets are approved.

导言:STRIDE 共识建议,除了将临床终点作为治疗目标外,还应根据生物标志物和内窥镜检查关注粘膜愈合。这篇叙述性综述对克罗恩病中的这一概念进行了批判:我们分析并讨论了终点作为目标的局限性、其目前有限的可实现性以及与'按目标治疗'相关的有争议的证据。专家观点:所有目标和终点都有其局限性:所有目标和终点都有其局限性,即使达到了目标,也并非所有目标和终点都能明确改善预后。STRIDE 的主要不足之处不仅在于缺乏对终点的验证和共识,而且几乎没有证据表明,通过调整剂量、时间或更换药物,可以使相当一部分患者达到这些终点。最重要的是,这一概念应建立在明确的证据基础上,即患者确实能从适当的治疗升级中获益,而这方面的相关对照研究一直存在争议。在 STRIDE 方法被证明优于以临床福祉为重点的标准治疗之前,该领域应保持缄默,并期待在批准新目标之前获得更多令人信服的证据。
{"title":"To STRIDE or not to STRIDE: a critique of \"treat to target\" in Crohn´s disease.","authors":"Klaus R Herrlinger, Eduard F Stange","doi":"10.1080/17474124.2023.2296564","DOIUrl":"10.1080/17474124.2023.2296564","url":null,"abstract":"<p><strong>Introduction: </strong>The STRIDE consensus suggested to focus on mucosal healing, based on biomarkers and endoscopy, in addition to clinical endpoints as treatment target. This narrative review provides a critique of this concept in Crohn´s disease.</p><p><strong>Areas covered: </strong>We analyze and discuss the limitations of endpoints as targets, their currently limited achievability, and the controversial evidence relating to 'treat to target.' The relevant publications in Pubmed were identified in a literature review with the key word 'Crohn´s disease.'</p><p><strong>Expert opinion: </strong>All targets and endpoints have their limitations, and, even if reached, not all have unequivocally been shown to improve prognosis. The major deficiency of STRIDE is not only the lack of validation and agreement upon endpoints but little evidence of their achievability in a sizable proportion of patients by dose or timing adjustments or switching the medication. Above all, the concept should be based on clear evidence that patients indeed benefit from appropriate escalation of treatment and relevant controlled studies in this regard have been controversial. Until the STRIDE approach is proven to be superior to standard treatment focusing on clinical well-being, the field should remain reluctant and expect more convincing evidence before new targets are approved.</p>","PeriodicalId":12257,"journal":{"name":"Expert Review of Gastroenterology & Hepatology","volume":" ","pages":"1205-1219"},"PeriodicalIF":3.9,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138829123","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Nosocomial spontaneous bacterial peritonitis is associated with high mortality - a systematic review and meta-analysis. 医院源性自发性细菌性腹膜炎与高死亡率相关——一项系统综述和荟萃分析。
IF 3.9 3区 医学 Q2 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2023-12-01 Epub Date: 2024-01-17 DOI: 10.1080/17474124.2023.2284825
Mubeen Khan Mohammed Abdul, Karim T Osman, Joseph M Cappuccio, Carol Spencer, Sanjaya K Satapathy

Introduction: It is unclear if Nosocomial Spontaneous Bacteria Peritonitis (NSBP) is associated with higher mortality compared with community acquired spontaneous bacterial peritonitis.

Methods: Database search from inception to May 2022 was conducted. The databases included MEDLINE, EMBASE, Cochrane registry of Controlled Trials, Cochrane Database of Systematic Reviews, and Scopus. Inclusion criteria were as follows: adult patients, age >18 years, with a diagnosis of NSBP. Pooled estimates of mortality were calculated following the restricted maximum likelihood method. The mortality rate between NSBP and CA-SBP was reported as odds ratio (OR) and 95% confidence interval (CI). Data synthesis was obtained using random effects meta-analysis. Heterogeneity was reported as I2.

Results: A total of 482 unique titles were screened. Twenty-two articles were included. A total of 2,145 patients with NSBP were included. Patients were followed for a median of 90 days. The pooled mortality rate of NSBP was 52.51% (95% CI 42.77-62.06%; I2 83.72%). Seven studies compared the mortality outcome of patients with NSBP and CA-SBP. NSBP was significantly associated with a higher rate of mortality (OR 2.78, 95% CI 1.87-4.11; I2 36.00%).

Conclusion: NSBP was associated with higher mortality rate compared to CA-SBP, which could be due to a higher rate of resistance organisms.

与社区获得性自发性细菌性腹膜炎相比,目前尚不清楚院内自发性细菌性腹膜炎(NSBP)是否与更高的死亡率相关。方法:检索自成立至2022年5月的数据库。MEDLINE, EMBASE, Cochrane对照试验注册,Cochrane系统评价数据库和Scopus。纳入标准:成人患者,年龄bb0 - 18岁,诊断为NSBP。死亡率的汇总估计是根据限制最大似然法计算的。以优势比(OR)和95%可信区间(CI)报告NSBP和CA-SBP之间的死亡率。数据综合采用随机效应荟萃分析。异质性报告为I2。结果:共筛选出482种独特题型。共纳入22篇文章。共有2145名NSBP患者被纳入研究。患者的随访时间中位数为90天。NSBP合并死亡率为52.51% (95%CI 42.77 ~ 62.06%;I2 83.72%)。七项研究比较了NSBP和CA-SBP患者的死亡率结果。NSBP与较高的死亡率显著相关(OR 2.78, 95%CI 1.87-4.11;I2 36.00%)。结论:与CA-SBP相比,NSBP与更高的死亡率相关,这可能是由于更高的耐药菌率。
{"title":"Nosocomial spontaneous bacterial peritonitis is associated with high mortality - a systematic review and meta-analysis.","authors":"Mubeen Khan Mohammed Abdul, Karim T Osman, Joseph M Cappuccio, Carol Spencer, Sanjaya K Satapathy","doi":"10.1080/17474124.2023.2284825","DOIUrl":"10.1080/17474124.2023.2284825","url":null,"abstract":"<p><strong>Introduction: </strong>It is unclear if Nosocomial Spontaneous Bacteria Peritonitis (NSBP) is associated with higher mortality compared with community acquired spontaneous bacterial peritonitis.</p><p><strong>Methods: </strong>Database search from inception to May 2022 was conducted. The databases included MEDLINE, EMBASE, Cochrane registry of Controlled Trials, Cochrane Database of Systematic Reviews, and Scopus. Inclusion criteria were as follows: adult patients, age >18 years, with a diagnosis of NSBP. Pooled estimates of mortality were calculated following the restricted maximum likelihood method. The mortality rate between NSBP and CA-SBP was reported as odds ratio (OR) and 95% confidence interval (CI). Data synthesis was obtained using random effects meta-analysis. Heterogeneity was reported as I<sup>2</sup>.</p><p><strong>Results: </strong>A total of 482 unique titles were screened. Twenty-two articles were included. A total of 2,145 patients with NSBP were included. Patients were followed for a median of 90 days. The pooled mortality rate of NSBP was 52.51% (95% CI 42.77-62.06%; I<sup>2</sup> 83.72%). Seven studies compared the mortality outcome of patients with NSBP and CA-SBP. NSBP was significantly associated with a higher rate of mortality (OR 2.78, 95% CI 1.87-4.11; I<sup>2</sup> 36.00%).</p><p><strong>Conclusion: </strong>NSBP was associated with higher mortality rate compared to CA-SBP, which could be due to a higher rate of resistance organisms.</p>","PeriodicalId":12257,"journal":{"name":"Expert Review of Gastroenterology & Hepatology","volume":" ","pages":"1333-1339"},"PeriodicalIF":3.9,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138046685","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evaluating the molecular and genetic mechanisms underlying gut motility disorders. 评估肠道运动紊乱的分子和遗传机制。
IF 3.9 3区 医学 Q2 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2023-12-01 Epub Date: 2024-01-17 DOI: 10.1080/17474124.2023.2296558
Atchariya Chanpong, Maria M Alves, Elena Bonora, Roberto De Giorgio, Nikhil Thapar

Introduction: Gastrointestinal (GI) motility disorders comprise a wide range of different diseases affecting the structural or functional integrity of the GI neuromusculature. Their clinical presentation and burden of disease depends on the predominant location and extent of gut involvement as well as the component of the gut neuromusculature affected.

Areas covered: A comprehensive literature review was conducted using the PubMed and Medline databases to identify articles related to GI motility and functional disorders, published between 2016 and 2023. In this article, we highlight the current knowledge of molecular and genetic mechanisms underlying GI dysmotility, including disorders of gut-brain interaction, which involve both GI motor and sensory disturbance.

Expert opinion: Although the pathophysiology and molecular mechanisms underlying many such disorders remain unclear, recent advances in the assessment of intestinal tissue samples, genetic testing with the application of 'omics' technologies and the use of animal models will provide better insights into disease pathogenesis as well as opportunities to improve therapy.

导言:胃肠道(GI)运动障碍包括一系列影响胃肠道神经肌肉结构或功能完整性的不同疾病。其临床表现和疾病负担取决于肠道受累的主要部位和程度,以及受影响的肠道神经肌肉的组成部分:我们使用 PubMed 和 Medline 数据库进行了全面的文献综述,以确定 2016-2023 年间发表的与肠道运动和功能性疾病相关的文章。在这篇文章中,我们重点介绍了目前有关消化道运动障碍的分子和遗传机制的知识,包括涉及消化道运动和感觉障碍的肠脑相互作用紊乱:尽管许多此类疾病的病理生理学和分子机制仍不清楚,但最近在肠道组织样本评估、应用'omics'技术进行基因检测以及使用动物模型方面取得的进展,将为我们提供更好的疾病发病机制见解以及改善治疗的机会。
{"title":"Evaluating the molecular and genetic mechanisms underlying gut motility disorders.","authors":"Atchariya Chanpong, Maria M Alves, Elena Bonora, Roberto De Giorgio, Nikhil Thapar","doi":"10.1080/17474124.2023.2296558","DOIUrl":"10.1080/17474124.2023.2296558","url":null,"abstract":"<p><strong>Introduction: </strong>Gastrointestinal (GI) motility disorders comprise a wide range of different diseases affecting the structural or functional integrity of the GI neuromusculature. Their clinical presentation and burden of disease depends on the predominant location and extent of gut involvement as well as the component of the gut neuromusculature affected.</p><p><strong>Areas covered: </strong>A comprehensive literature review was conducted using the PubMed and Medline databases to identify articles related to GI motility and functional disorders, published between 2016 and 2023. In this article, we highlight the current knowledge of molecular and genetic mechanisms underlying GI dysmotility, including disorders of gut-brain interaction, which involve both GI motor and sensory disturbance.</p><p><strong>Expert opinion: </strong>Although the pathophysiology and molecular mechanisms underlying many such disorders remain unclear, recent advances in the assessment of intestinal tissue samples, genetic testing with the application of 'omics' technologies and the use of animal models will provide better insights into disease pathogenesis as well as opportunities to improve therapy.</p>","PeriodicalId":12257,"journal":{"name":"Expert Review of Gastroenterology & Hepatology","volume":" ","pages":"1301-1312"},"PeriodicalIF":3.9,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138829121","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Preoperative endoscopic ultrasound-guided biliary drainage for primary drainage in obstructive jaundice. 术前内镜超声引导胆道引流术,用于梗阻性黄疸的初次引流。
IF 3.9 3区 医学 Q2 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2023-12-01 Epub Date: 2024-01-17 DOI: 10.1080/17474124.2023.2293813
Shuntaro Mukai, Takao Itoi

Introduction: Endoscopic transpapillary approach by endoscopic retrograde cholangiopancreatography (ERCP) is the established technique for preoperative biliary drainage (PBD). Recently, endoscopic ultrasound-guided biliary drainage (EUS-BD) has been reported to be a useful alternative technique after ERCP fail. However, the optimal strategy remain controversial.

Area covered: This review summarizes the literature on EUS-BD techniques for PBD with a literature search using PubMed, Web of Science, and the Cochrane Central Register of Controlled Trials database between 2000 and 2023 using keywords for 'preoperative biliary drainage' and all types of EUS-BD techniques.

Expert opinion: As there is no consensus on the optimal EUS-BD technique for PBD, selection of the EUS-BD approach depends on the patient's condition, the biliary obstruction site, the anastomosis after surgical intervention, and the preference of the endoscopist. However, we consider that EUS-HGS using a dedicated plastic stent may have some advantages in the adverse impact of surgical procedure because the location where the fistula is created by EUS-HGS is away from the site of the surgical procedure. Although there remain many issues that require further investigation, EUS-BD can be a feasible and safe alternative method of PBD for malignant biliary obstruction after ERCP fail.

导言:通过内镜逆行胰胆管造影术(ERCP)进行内镜下经胆管引流(PBD)是目前公认的术前胆道引流(PBD)技术。最近,有报道称内镜超声引导胆道引流术(EUS-BD)是ERCP失败后的一种有效替代技术。然而,最佳策略仍存在争议:本综述通过使用 PubMed、Web of Science 和 Cochrane Central Register of Controlled Trials 数据库,以 "术前胆道引流 "和所有类型的 EUS-BD 技术为关键词,对 2000 年至 2023 年期间有关 EUS-BD 技术用于 PBD 的文献进行了检索:专家意见:由于目前尚未就 PBD 的最佳 EUS-BD 技术达成共识,EUS-BD 方法的选择取决于患者的病情、胆道梗阻部位、手术干预后的吻合情况以及内镜医师的偏好。不过,我们认为使用专用塑料支架的 EUS-HGS 可能在手术的不利影响方面具有一些优势,因为 EUS-HGS 创建瘘管的位置远离手术部位。尽管仍有许多问题需要进一步研究,但 EUS-BD 可以作为 ERCP 失败后恶性胆道梗阻的一种可行且安全的 PBD 替代方法。
{"title":"Preoperative endoscopic ultrasound-guided biliary drainage for primary drainage in obstructive jaundice.","authors":"Shuntaro Mukai, Takao Itoi","doi":"10.1080/17474124.2023.2293813","DOIUrl":"10.1080/17474124.2023.2293813","url":null,"abstract":"<p><strong>Introduction: </strong>Endoscopic transpapillary approach by endoscopic retrograde cholangiopancreatography (ERCP) is the established technique for preoperative biliary drainage (PBD). Recently, endoscopic ultrasound-guided biliary drainage (EUS-BD) has been reported to be a useful alternative technique after ERCP fail. However, the optimal strategy remain controversial.</p><p><strong>Area covered: </strong>This review summarizes the literature on EUS-BD techniques for PBD with a literature search using PubMed, Web of Science, and the Cochrane Central Register of Controlled Trials database between 2000 and 2023 using keywords for 'preoperative biliary drainage' and all types of EUS-BD techniques.</p><p><strong>Expert opinion: </strong>As there is no consensus on the optimal EUS-BD technique for PBD, selection of the EUS-BD approach depends on the patient's condition, the biliary obstruction site, the anastomosis after surgical intervention, and the preference of the endoscopist. However, we consider that EUS-HGS using a dedicated plastic stent may have some advantages in the adverse impact of surgical procedure because the location where the fistula is created by EUS-HGS is away from the site of the surgical procedure. Although there remain many issues that require further investigation, EUS-BD can be a feasible and safe alternative method of PBD for malignant biliary obstruction after ERCP fail.</p>","PeriodicalId":12257,"journal":{"name":"Expert Review of Gastroenterology & Hepatology","volume":" ","pages":"1197-1204"},"PeriodicalIF":3.9,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138829122","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Securing the diagnosis of HRS-AKI: implications for current therapies. 确保rs - aki的诊断:对当前治疗的影响。
IF 3.9 3区 医学 Q2 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2023-12-01 Epub Date: 2024-01-17 DOI: 10.1080/17474124.2023.2284189
Arpan Mohanty, Andrés Cárdenas

Introduction: Hepatorenal syndrome (HRS)-acute kidney injury (HRS-AKI) is a specific type of kidney injury seen in patients with cirrhosis and ascites and is associated with high mortality and morbidity. It is characterized by rapid deterioration of renal function due to reduced renal blood flow secondary to portal hypertensive splanchnic and systemic vasodilation. Early diagnosis and treatment of HRS-AKI are associated with greater likelihood of improvement in renal function, lower need for dialysis, and better post-transplant outcomes.

Areas covered: This review discusses the diagnostic criteria for HRS-AKI, which has undergone several key changes over the last decade, with an aim to secure an early diagnosis and aid swift treatment initiation. Additionally, this review outlines the current treatment paradigms for HRS-AKI.

Expert opinion: In the last 20 years, there have been several advances in understanding the pathophysiology and natural course of HRS-AKI. These have led to critical changes in its definition and diagnostic algorithm. However, prognosis of HRS-AKI remains dismal with no significant improvement in HRS-AKI reversal or HRS-related mortality over this time. We discuss several gaps in the current understanding and management of HRS-AKI that will benefit from further research.

肝肾综合征(HRS)-急性肾损伤(HRS- aki)是一种特殊类型的肾损伤,见于肝硬化和腹水患者,具有高死亡率和发病率。它的特点是由于继发于门静脉高压、内脏和全身血管扩张的肾血流量减少而导致肾功能迅速恶化。HRS-AKI的早期诊断和治疗与肾功能改善的可能性更大、透析需求更低和移植后预后更好相关。涵盖领域:本综述讨论了rs - aki的诊断标准,该标准在过去十年中经历了几次关键变化,目的是确保早期诊断并帮助快速开始治疗。此外,这篇综述概述了目前的治疗范例rs - aki。专家意见:在过去的20年里,在了解rs - aki的病理生理和自然过程方面取得了一些进展。这些导致了其定义和诊断算法的重大变化。然而,rs - aki的预后仍然令人沮丧,在这段时间内rs - aki逆转或rs相关死亡率没有显著改善。我们讨论了目前对rs - aki的理解和管理中的几个空白,这些空白将从进一步的研究中受益。
{"title":"Securing the diagnosis of HRS-AKI: implications for current therapies.","authors":"Arpan Mohanty, Andrés Cárdenas","doi":"10.1080/17474124.2023.2284189","DOIUrl":"10.1080/17474124.2023.2284189","url":null,"abstract":"<p><strong>Introduction: </strong>Hepatorenal syndrome (HRS)-acute kidney injury (HRS-AKI) is a specific type of kidney injury seen in patients with cirrhosis and ascites and is associated with high mortality and morbidity. It is characterized by rapid deterioration of renal function due to reduced renal blood flow secondary to portal hypertensive splanchnic and systemic vasodilation. Early diagnosis and treatment of HRS-AKI are associated with greater likelihood of improvement in renal function, lower need for dialysis, and better post-transplant outcomes.</p><p><strong>Areas covered: </strong>This review discusses the diagnostic criteria for HRS-AKI, which has undergone several key changes over the last decade, with an aim to secure an early diagnosis and aid swift treatment initiation. Additionally, this review outlines the current treatment paradigms for HRS-AKI.</p><p><strong>Expert opinion: </strong>In the last 20 years, there have been several advances in understanding the pathophysiology and natural course of HRS-AKI. These have led to critical changes in its definition and diagnostic algorithm. However, prognosis of HRS-AKI remains dismal with no significant improvement in HRS-AKI reversal or HRS-related mortality over this time. We discuss several gaps in the current understanding and management of HRS-AKI that will benefit from further research.</p>","PeriodicalId":12257,"journal":{"name":"Expert Review of Gastroenterology & Hepatology","volume":" ","pages":"1233-1239"},"PeriodicalIF":3.9,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138046686","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A systematic review and meta-analysis on GERD after OAGB: rate, treatments, and success. 关于 OAGB 术后胃食管反流病的系统回顾和荟萃分析:发病率、治疗方法和成功率。
IF 3.9 3区 医学 Q2 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2023-12-01 Epub Date: 2024-01-17 DOI: 10.1080/17474124.2023.2296992
Amir Hossein Davarpanah Jazi, Shahab Shahabi, Erfan Sheikhbahaei, Salvatore Tolone, Mehdi El Skalli, Ali Kabir, Rohollah Valizadeh, Mohammad Kermansaravi

Introduction: This review aims to investigate the gastroesophageal reflux disease (GERD) as one of the important concerns for both surgeons and patients after one anastomosis gastric bypass (OAGB).

Method: PubMed, Scopus, Embase, Web of Science, and Cochrane were reviewed by the end of the 2021 with keywords relating to GERD, OAGB, and their equivalents. Data regarding OAGB, number of patients with GERD, treatment for GERD, endoscopy findings, the interval between GERD and OAGB were retrieved by two independent investigators. The primary effect/effect size measure was prevalence.

Results: 40 studies examining 17,299 patients were included revealing that 2% of patients experience GERD following OAGB. Reflux after revisional OAGB is six times higher than primary OAGB. Despite being unclear, medical and surgical treatments for GERD after OAGB were used in 60% and 41% of patients with estimated success rate of 85% and 100%, respectively.

Conclusion: Based on how GERD was identified after OAGB, its rate ranged from 0 to 55%; the pooled rate of 2% is near to Roux-en-Y gastric bypass. GERD symptoms can be mild to be tolerated without medical treatment, moderate that respond to acid-reducing agents, or severe enough that are categorized as interactable and would need a surgical intervention.

简介:本综述旨在研究胃食管反流病(GERD),该病是单吻合胃旁路术(OAGB)术后外科医生和患者共同关注的重要问题之一:方法:在 2021 年年底之前,对 PubMed、Scopus、Embase、Web of Science 和 Cochrane 进行了检索,检索关键词包括胃食管反流病、OAGB 及其同义词。两名独立研究人员检索了有关 OAGB、胃食管反流患者人数、胃食管反流治疗、内镜检查结果、胃食管反流与 OAGB 之间间隔的数据。效果/效应大小的主要衡量标准是患病率:结果:共纳入了 40 项研究,对 17,299 名患者进行了检查,结果显示 2% 的患者在接受 OAGB 手术后会出现胃食管反流。修正 OAGB 后的反流率是原发性 OAGB 的六倍。尽管尚不明确,但有 60% 和 41% 的患者在 OAGB 术后采用了药物和手术治疗胃食管反流病,估计成功率分别为 85% 和 100%:根据 OAGB 术后胃食管反流病的识别方式,其发生率从 0% 到 55% 不等;2% 的总发生率接近 Roux-en-Y 胃旁路术。胃食管反流症状可以是轻度的,无需药物治疗即可忍受;也可以是中度的,对减酸剂有反应;还可以是重度的,被归类为可相互作用的症状,需要手术治疗。
{"title":"A systematic review and meta-analysis on GERD after OAGB: rate, treatments, and success.","authors":"Amir Hossein Davarpanah Jazi, Shahab Shahabi, Erfan Sheikhbahaei, Salvatore Tolone, Mehdi El Skalli, Ali Kabir, Rohollah Valizadeh, Mohammad Kermansaravi","doi":"10.1080/17474124.2023.2296992","DOIUrl":"10.1080/17474124.2023.2296992","url":null,"abstract":"<p><strong>Introduction: </strong>This review aims to investigate the gastroesophageal reflux disease (GERD) as one of the important concerns for both surgeons and patients after one anastomosis gastric bypass (OAGB).</p><p><strong>Method: </strong>PubMed, Scopus, Embase, Web of Science, and Cochrane were reviewed by the end of the 2021 with keywords relating to GERD, OAGB, and their equivalents. Data regarding OAGB, number of patients with GERD, treatment for GERD, endoscopy findings, the interval between GERD and OAGB were retrieved by two independent investigators. The primary effect/effect size measure was prevalence.</p><p><strong>Results: </strong>40 studies examining 17,299 patients were included revealing that 2% of patients experience GERD following OAGB. Reflux after revisional OAGB is six times higher than primary OAGB. Despite being unclear, medical and surgical treatments for GERD after OAGB were used in 60% and 41% of patients with estimated success rate of 85% and 100%, respectively.</p><p><strong>Conclusion: </strong>Based on how GERD was identified after OAGB, its rate ranged from 0 to 55%; the pooled rate of 2% is near to Roux-en-Y gastric bypass. GERD symptoms can be mild to be tolerated without medical treatment, moderate that respond to acid-reducing agents, or severe enough that are categorized as interactable and would need a surgical intervention.</p>","PeriodicalId":12257,"journal":{"name":"Expert Review of Gastroenterology & Hepatology","volume":" ","pages":"1321-1332"},"PeriodicalIF":3.9,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139039714","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Imaging in pediatric disorders of the gut-brain interactions: current best practice and future directions. 儿童脑肠相互作用疾病的影像学:当前最佳实践和未来方向。
IF 3.9 3区 医学 Q2 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2023-12-01 Epub Date: 2024-01-17 DOI: 10.1080/17474124.2023.2288164
Shaman Rajindrajith, Wathsala Hathagoda, Eranga Ganewatte, Niranga Manjuri Devanarayana, Nikhil Thapar, Marc Benninga

Introduction: Disorders of Gut-Brain Interactions (DGBI) are a common clinical problem in children and pose significant challenges to the attending pediatrician. Radiological investigations are commonly ordered to evaluate these children.

Area covered: This review focuses on the current best practice of using radiological investigations in DGBIs and how novel radiological investigations could revolutionize the assessment and therapeutic approach of DGBI in children.

Expert opinion: We believe imaging in DGBI is still in its early stages, but it has the potential to revolutionize how we diagnose and treat children with DGBI. As the understanding of the gut-brain axis continues to grow, we can expect to see the disappearance of conventional imaging techniques and the emergence of more sophisticated imaging techniques with less radiation exposure in the future which provide more clinically meaningful information regarding the gut-brain axis and its influence on intestinal function. Some of the novel imaging modalities will be able to broaden our horizon of understanding DGBI in children providing more useful therapeutic options to minimize their suffering.

肠脑相互作用障碍(DGBI)是儿童常见的临床问题,对儿科医生提出了重大挑战。通常要求进行放射检查来评估这些儿童。涵盖领域:本综述着重于目前在DGBI中使用放射学检查的最佳实践,以及新的放射学检查如何彻底改变儿童DGBI的评估和治疗方法。专家意见:我们认为DGBI的成像仍处于早期阶段,但它有可能彻底改变我们对DGBI儿童的诊断和治疗方式。随着对肠-脑轴的理解不断加深,我们可以期待看到传统成像技术的消失,未来出现更复杂、辐射暴露更少的成像技术,这些技术将为肠-脑轴及其对肠道功能的影响提供更多有临床意义的信息。一些新的成像方式将能够拓宽我们对儿童DGBI的理解,提供更多有用的治疗选择,以尽量减少他们的痛苦。
{"title":"Imaging in pediatric disorders of the gut-brain interactions: current best practice and future directions.","authors":"Shaman Rajindrajith, Wathsala Hathagoda, Eranga Ganewatte, Niranga Manjuri Devanarayana, Nikhil Thapar, Marc Benninga","doi":"10.1080/17474124.2023.2288164","DOIUrl":"10.1080/17474124.2023.2288164","url":null,"abstract":"<p><strong>Introduction: </strong>Disorders of Gut-Brain Interactions (DGBI) are a common clinical problem in children and pose significant challenges to the attending pediatrician. Radiological investigations are commonly ordered to evaluate these children.</p><p><strong>Area covered: </strong>This review focuses on the current best practice of using radiological investigations in DGBIs and how novel radiological investigations could revolutionize the assessment and therapeutic approach of DGBI in children.</p><p><strong>Expert opinion: </strong>We believe imaging in DGBI is still in its early stages, but it has the potential to revolutionize how we diagnose and treat children with DGBI. As the understanding of the gut-brain axis continues to grow, we can expect to see the disappearance of conventional imaging techniques and the emergence of more sophisticated imaging techniques with less radiation exposure in the future which provide more clinically meaningful information regarding the gut-brain axis and its influence on intestinal function. Some of the novel imaging modalities will be able to broaden our horizon of understanding DGBI in children providing more useful therapeutic options to minimize their suffering.</p>","PeriodicalId":12257,"journal":{"name":"Expert Review of Gastroenterology & Hepatology","volume":" ","pages":"1255-1266"},"PeriodicalIF":3.9,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138298850","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Strengths and limitations of risk stratification tools for patients with upper gastrointestinal bleeding: a narrative review. 上消化道出血患者风险分层工具的优势和局限性:叙述性综述。
IF 3.9 3区 医学 Q2 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2023-07-01 Epub Date: 2023-07-31 DOI: 10.1080/17474124.2023.2242252
Ali A Alali, Antoine Boustany, Myriam Martel, Alan N Barkun

Introduction: Despite advances in the management of patients with upper gastrointestinal bleeding (UGIB), associated morbidity and mortality remain significant. Most patients, however, will experience favorable outcomes without a need for hospital-based interventions. Risk assessment scores may assist in such early risk-stratification. These scales may optimize identification of low-risk patients, resulting in better resource utilization, including a reduced need for early endoscopy and fewer hospital admissions. The aim of this article is to provide an updated detailed review of risk assessment scores in UGIB.

Area covered: A literature review identified past and currently available pre-endoscopic risk assessment scores for UGIB, with a focus on low-risk prediction. Strengths and weaknesses of the different scales are discussed as well as their impact on clinical decision-making.

Expert opinion: The current evidence supports using the Glasgow Blatchford Score as it is the most accurate tool available when attempting to identify low-risk patients who can be safely managed on an outpatient basis. Currently, no risk assessment tool appears accurate enough in confidently classifying patients as high risk. Future research should utilize more standardized methodologies, while favoring interventional trial designs to better characterize the clinical impact attributable to the use of such risk stratification schemes.

引言:尽管上消化道出血(UGIB)患者的治疗取得了进展,但相关的发病率和死亡率仍然很高。然而,大多数患者将在不需要医院干预的情况下获得良好的结果。风险评估分数可能有助于这种早期风险分层。这些量表可以优化低风险患者的识别,从而更好地利用资源,包括减少对早期内窥镜检查的需求和减少住院人数。本文的目的是对UGIB中的风险评估分数进行最新的详细审查。涵盖领域:一项文献综述确定了UGIB过去和目前可用的内镜前风险评估评分,重点是低风险预测。讨论了不同量表的优势和劣势,以及它们对临床决策的影响。专家意见:目前的证据支持使用Glasgow Blatchford评分,因为它是在试图识别可以在门诊安全管理的低风险患者时最准确的工具。目前,似乎没有一种风险评估工具足够准确,可以自信地将患者归类为高风险患者。未来的研究应该使用更标准化的方法,同时支持介入试验设计,以更好地描述使用此类风险分层方案的临床影响。
{"title":"Strengths and limitations of risk stratification tools for patients with upper gastrointestinal bleeding: a narrative review.","authors":"Ali A Alali,&nbsp;Antoine Boustany,&nbsp;Myriam Martel,&nbsp;Alan N Barkun","doi":"10.1080/17474124.2023.2242252","DOIUrl":"10.1080/17474124.2023.2242252","url":null,"abstract":"<p><strong>Introduction: </strong>Despite advances in the management of patients with upper gastrointestinal bleeding (UGIB), associated morbidity and mortality remain significant. Most patients, however, will experience favorable outcomes without a need for hospital-based interventions. Risk assessment scores may assist in such early risk-stratification. These scales may optimize identification of low-risk patients, resulting in better resource utilization, including a reduced need for early endoscopy and fewer hospital admissions. The aim of this article is to provide an updated detailed review of risk assessment scores in UGIB.</p><p><strong>Area covered: </strong>A literature review identified past and currently available pre-endoscopic risk assessment scores for UGIB, with a focus on low-risk prediction. Strengths and weaknesses of the different scales are discussed as well as their impact on clinical decision-making.</p><p><strong>Expert opinion: </strong>The current evidence supports using the Glasgow Blatchford Score as it is the most accurate tool available when attempting to identify low-risk patients who can be safely managed on an outpatient basis. Currently, no risk assessment tool appears accurate enough in confidently classifying patients as high risk. Future research should utilize more standardized methodologies, while favoring interventional trial designs to better characterize the clinical impact attributable to the use of such risk stratification schemes.</p>","PeriodicalId":12257,"journal":{"name":"Expert Review of Gastroenterology & Hepatology","volume":"17 8","pages":"795-803"},"PeriodicalIF":3.9,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10125423","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
期刊
Expert Review of Gastroenterology & Hepatology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1